| Name | Title | Contact Details |
|---|
Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.
We are pioneering a better drug discovery process using systems biology to improve the lives of people with neurodegenerative disorders.
Exothera is a CDMO delivering customized process development and GMP production services for viral vectors in Belgium
Vital Probes Inc is a Jermyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.